Larson Financial Group’s Sage Therapeutics SAGE Stock Holding History

Larson Financial Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$398	–	3474
2025 Q1	$398	Buy	+50	New	+$366	﹤0.01%	2635
2023 Q1	–	Sell	-59	Closed	-$2.25K	–	1599
2022 Q4	$2.25K	Buy	+59	New	+$2.25K	﹤0.01%	1174

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Larson Financial Group's SAGE Position: Q2 2025 in Review

Larson Financial Group sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 50 shares — an estimated $398 sold.

Larson Financial Group first reported a position in SAGE in Q4 2022 and held it in 2 quarters. The position peaked at $2.25K in Q4 2022. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Larson Financial Group reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Larson Financial Group sold 50 Sage Therapeutics shares in Q2 2025, an estimated $398.
Larson Financial Group first reported a position in Sage Therapeutics in Q4 2022 and held it in 2 quarters.
Larson Financial Group's Sage Therapeutics position peaked at $2.25K in Q4 2022.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Larson Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.